NEW YORK (GenomeWeb) – Canadian RNAi drug developer Tekmira Pharmaceuticals has announced that it has agreed to merge with US-based OnCore Biopharma to create a new company focused on an oral cure for hepatitis B virus infection.

As a result of the transaction, which is expected to close in the first half of this year, Tekmira will shift away from being a pure-play RNAi drug firm aiming to use the gene-silencing technology to treat multiple different diseases to a company focused on developing multiple technologies against a single indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.